Sugi Predict

Sugi Predict / Compounds / SCHEMBL1765772

SCHEMBL1765772

SCHEMBL1765772

Cc1cc(N)cnc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 3/20 0.47
▸ MKNK1 Q9BUB5 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ TRPV1 Q8NER1 5/20 0.41
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ KIT P10721 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ KDR P35968 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ KDM1A O60341 1/20 0.38
▸ MAOB P27338 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2653413 0.92 TRPV1 (0.42) KIF11MKNK1MKNK2TRPV1KIT
SCHEMBL1773669 0.85 DGAT1 (0.44) KIF11TRPV1KDM4EALDH1A1POLB
SCHEMBL1765224 0.81 KIF11 (0.47) KIF11MKNK1MKNK2TRPV1KDM4E
SCHEMBL16685761 0.80 FYN (0.42) ALDH1A1SMN1; SMN2PTGS1LMNAPDK1
SCHEMBL13538832 0.78 RAB9A (0.47) TRPV1KDM4ESMN1; SMN2HPGD
SCHEMBL9950905 0.78 ADORA2A (0.43) TRPV1KDM4EALDH1A1SMN1; SMN2CYP1A2
SCHEMBL2406888 0.78 PDK1 (0.46) KDM4EALDH1A1POLBSMN1; SMN2KDR
SCHEMBL1765253 0.75 MAPT (0.48) TRPV1KDM4EALDH1A1
SCHEMBL6839503 0.74 PTPN11 (0.42) ALDH1A1KDM1AMAOBMAP4K4
SCHEMBL11375723 0.74 MKNK1 (0.44) KIF11MKNK1MKNK2ALDH1A1MYC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 — — US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 — — US disclosed
US-20150266861-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-09-24 — — US disclosed
CN-103261165-B Glucagon receptor modulators PFIZER INC. (US) 2015-08-26 — — CN disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 — — US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 — — US disclosed
US-9056834-B2 Glucagon receptor modulators PFIZER INC. (US) 2015-06-16 — — US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 — — US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 — — US disclosed
US-20150094338-A1 Glucagon Receptor Modulators PFIZER INC. (US) 2015-04-02 — — US disclosed
CN-1968921-B Glucagon receptor antagonists, preparation and therapeutic uses LILLY CO ELI 2011-11-23 — — CN disclosed
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2011-05-26 — — US disclosed
US-20100324140-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2010-12-23 — — US disclosed
US-7816557-B2 3-{4-[1-(4'-tert-butyl-2,6-dimethyl-biphenyl-4-yloxy)-4,4,4-trifluoro-butyl]-benzoylamino}-propionic acid; treat diabetic and other glucagon related metabolic disorders ELI LILLY AND COMPANY (US) 2010-10-19 — — US disclosed
EP-2159221-A1 Glucagon receptor antagonists, preparation and therapeutic uses Eli Lilly & Company (US) 2010-03-03 — — EP disclosed
EP-1758853-B1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2010-01-20 — — EP disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
CN-1968921-A Glucagon receptor antagonists, preparation and therapeutic uses LILLY CO ELI (US) 2007-05-23 — — CN disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 — — EP disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124648-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES GLP1R, GCGR, GIPR KIF11 4170/4885MKNK1 1814/4885MKNK2 2052/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR KIF11 4170/4885MKNK1 1814/4885MKNK2 2052/4885
US-20150094338-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 KIF11 4048/4885MKNK1 2037/4885MKNK2 2293/4885
US-20100324140-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES GLP1R, GCGR, GIPR KIF11 4170/4885MKNK1 1814/4885MKNK2 2052/4885
US-20150266861-A1 Glucagon Receptor Modulators GLP1R, GCGR, GPR119 KIF11 4048/4885MKNK1 2037/4885MKNK2 2293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.